Revumenib Chemical Structure. CAS No. : 2169919-21-3
Revumenib Chemical Structure. CAS No. : 2169919-21-3
Revumenib
HY-136175
CAS Number2169919-21-3
Product group Chemicals
Estimated Purity99.88
Molecular Weight630.82
Overview
- SupplierMedChem Express
- Product NameRevumenib [2169919-21-3]
- Delivery Days Customer9
- CAS Number2169919-21-3
- CertificationResearch Use Only
- Estimated Purity99.88
- Molecular FormulaC32H47FN6O4S
- Molecular Weight630.82
- Scientific DescriptionRevumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K i of 0.149 nM and a cell based IC 50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1] .
- SMILESO=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200
References
- Yan F, Li J, Milosevic J, et al. Kat6a and enl form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs. Cancer Discov. 2022;12(3):792-811.Read more
- Nguyen N, Gudmundsson KO, Soltis AR, et al. Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. iScience. 2022;25(1):103679.Read more
- Barajas JM, Rasouli M, Umeda M, et al. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood. 2024;143(7):619-630.Read more
- Mill CP, Fiskus W, Das K, et al. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023;37(6):1336-1348.Read more